Wedbush Upgrades Keros Therapeutics (NASDAQ:KROS) to Strong-Buy

Wedbush upgraded shares of Keros Therapeutics (NASDAQ:KROS - Free Report) to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. Wedbush also issued estimates for Keros Therapeutics' Q4 2025 earnings at ($1.27) EPS.

Several other research analysts have also issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They issued an "overweight" rating for the company. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research note on Tuesday. They issued a "buy" rating for the company. Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a "buy" rating and a $96.00 price target for the company. Scotiabank assumed coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $77.00 price target for the company. Finally, Bank of America decreased their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a research note on Thursday, September 12th. Eleven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $89.11.

Keros Therapeutics Trading Up 6.2 %

KROS traded up $3.87 during trading on Monday, hitting $66.45. 534,406 shares of the stock traded hands, compared to its average volume of 308,784. The firm has a 50-day moving average of $56.87 and a 200 day moving average of $51.89. Keros Therapeutics has a 12-month low of $27.31 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The company had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same period last year, the company posted ($1.27) earnings per share. On average, research analysts anticipate that Keros Therapeutics will post -4.9 EPS for the current year.

Insider Activity at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now directly owns 119,522 shares of the company's stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 22.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. Mirae Asset Global Investments Co. Ltd. raised its position in Keros Therapeutics by 1.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company's stock valued at $870,000 after purchasing an additional 251 shares during the period. Ameritas Investment Partners Inc. raised its position in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company's stock valued at $169,000 after purchasing an additional 324 shares during the period. KBC Group NV raised its position in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after purchasing an additional 432 shares during the period. Arizona State Retirement System raised its position in Keros Therapeutics by 16.3% during the second quarter. Arizona State Retirement System now owns 8,077 shares of the company's stock valued at $369,000 after purchasing an additional 1,130 shares during the period. Finally, American International Group Inc. raised its position in Keros Therapeutics by 13.1% during the first quarter. American International Group Inc. now owns 12,653 shares of the company's stock valued at $838,000 after purchasing an additional 1,465 shares during the period. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.